Mechanism of Action of Ustekinumab in Psoriatic Arthritis

Arthritis, Psoriatic Clinical Trial

— MoA anti-p40  

Official title:

Mechanism of Action Study of Ustekinumab Treatment in Psoriatic Arthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03565042
• Other study ID #: AMC_50218_MoA anti-p40
• Status: Recruiting
• Start date: December 8, 2015
• Est. completion date: November 2018

Study information

• Verified date: June 2018
• Source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Contact: Dominique LP Baeten, MD PhD Prof
• Phone: 00312056
• Email: d.l.baeten[@]amc.uva.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine the mechanism of action on target tissue level of ustekinumab treatment in psoriatic arthritis patients.

Patients who are planning to start treatment with anti-p40 therapy (ustekinumab) will be included in the trial.

At week 0, 12 and 24 peripheral blood, synovial tissue and skin will be obtained and analysed with different techniques to assess the effect of the therapy on inflammatory pathways.

Description:

Rationale:

The overall aim of the study is to determine which downstream cellular and molecular pathways involved in psoriatic arthritis (PsA) pathogenesis are modulated by Interleukine 23/Interleukine12 P40 subunit (IL23/12 P40) blockade. As we have ample evidence that relevant disease-specific pathways are found in the primary target tissues, in particular in synovial tissue obtained from peripheral joints, but not in peripheral blood, we will strongly focus on this compartment by obtaining paired biopsies before and after treatment.

Objectives:

The primary objective is to assess the effect of IL23/12 P40 blockade on cellular en molecular pathways involved in PsA disease in the synovium, in the synovial fluid and peripheral blood.

The secondary objective is to compare which cellular/molecular disease pathways are affected by IL23/12 P40 blockade and not by tumour necrosis factor (TNF) blockade and thereby identify molecular biomarkers which may help to determine which patients may benefit from this treatment in comparison with anti-TNF treatment.

Study design:

Single centre, 24-week open-label study in subjects with clinically active peripheral psoriatic arthritis receiving treatment with ustekinumab.

Synovial biopsies will be obtained from patients before and after 12 and 24 weeks of treatment with ustekinumab.

Study population:

Patients with a diagnosis of psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. In total 16 patients will be included.

Intervention: Blood withdrawal and mini-arthroscopies at different timepoints.

Main study parameters/endpoints:

Primary study parameters/outcome of the study:

• Changes in the synovial cellular infiltrate and molecular pathways influenced between baseline and week 12/ week24

Secondary study parameters/outcome of the study:

• Comparison of the synovial molecular changes induced by anti-p40 with the changes induced by anti-TNF (analysed in historical samples in a similar patient population and study setting)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 16
• Est. completion date: November 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female patients age > 18 years diagnosed with Psoriatic Arthritis according to the CASPAR criteria

• Patient for whom the treating physician has decided to prescribe in the usual manner:

Ustekinumab (Stelara) (45mg/ injection, given on week 0, 4, and every 12 weeks thereafter)

• Active disease defined by =1 swollen and = 1 tender joint, and at least 1 swollen knee or ankle joint at baseline

Exclusion Criteria:

• Contraindications for needle-arthroscopy such as joint replacement (in the affected knee or ankle joint).

• Use of any investigational drug and/or devices within 4 weeks of baseline, or a period of 5 half-lives of the investigational drug, whichever is longer.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic

Intervention

Procedure:
• Arthroscopy
Arthroscopy of swollen joint (ankle/knee)

Locations

Country	Name	City	State
Netherlands	Academic Medical Center Amsterdam	Amsterdam	Noord-Holland

Sponsors (1)

Lead Sponsor	Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	biological effect of anti TNF v.s. anti IL23/IL12 p40 on synovium obtained from a swollen knee or ankle.	molecular and cellular changes affected by anti IL23/IL12 p40 and not by anit TNF therapy.	week 0 compared with week 12 and week 24
Primary	Biological effect of treatment on synovium obtained via arthroscopy from a swollen knee or ankle.	Cellular and molecular changes of the synovium.	Cellular and molecular changes of the synovium of samples obtained at week 0 compared with week 12 and week 24.